Proxy Votes Now

Home › Funds › 1290 Funds › 1290 Essex Small Cap Growth Fund

1290 Essex Small Cap Growth Fund (ESCFX) proxy voting record 2025-2026

Fund family: 1290 Funds · Filed by 1290 Funds (CIK 1605941) · SEC series S000076802

Share classes and tickers: ESCFX (C000236850), ESCJX (C000236852), ESCKX (C000236849)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 769 with, 0 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with 1290 Funds as a whole

The same two figures as 1290 Funds’s manager page (13,565 ballot items across 6 funds and accounts), counted the same way for this fund.

2025-2026This fundItems1290 FundsItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)85.3%74891.7%11,367
Backed environmental and social shareholder proposals at US companiesn/a07.7%284

No item-level comparison with other 1290 Funds funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 82.8% of this fund’s 769 such votes could be given a sector; the other 132 (17.2%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Industrials14500.0%
Consumer Discretionary14200.0%
Health Care12400.0%
Technology8200.0%
Finance5500.0%
Energy3800.0%
Telecommunications1800.0%
Miscellaneous1400.0%
Real Estate1200.0%
Consumer Staples700.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5120
Audit-related1020
Say-on-Pay900
Compensation480
Corporate Governance200
Capital Structure60
Extraordinary Transactions20
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Adaptive Biotechnologies CorporationJune 5, 2026$3M40
Xeris Biopharma Holdings, Inc.June 4, 2026$3M40
Globalstar, Inc.May 13, 2026$2M40
Xometry, Inc.June 16, 2026$2M50
Leonardo DRS, Inc.May 14, 2026$2M110
Travere Therapeutics, Inc.May 19, 2026$2M140
Lincoln Educational Services CorporationMay 7, 2026$2M120
Ligand Pharmaceuticals IncorporatedJune 5, 2026$2M110

Search this fund’s votes by company

781 ballot items at 100 meetings in 2025-2026. Download all votes (CSV)

About this fund’s record

In the 2025-2026 proxy season, 1290 Essex Small Cap Growth Fund (ESCFX) voted at 100 shareholder meetings of 100 companies, on 781 ballot items in all. Where management made a recommendation, the fund followed it on 100.0% of the items and voted against it 0 times. It voted FOR the board's own proposals less often than 1290 Funds's funds as a whole (85.3% against 91.7%).

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of 1290 Funds’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.